BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the se

Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as t

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's str

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Ove

Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and rais

Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p

Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lo

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and

Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: EL

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the a

Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001  ef

Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 1

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a

Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p

Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and ra

This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gain

Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction

BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded War

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previo

US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus

Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%.

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ: ELVN), a clinical-stage biopharmaceutic

61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR

Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad

Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rati

Enliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2

Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.

This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sa

BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Na

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates i

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Posit

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achievin

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achievin

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and

Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a

Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and rais